Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Total Current Liabilities
All obligations due within one year.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 18.6% from a year ago
Total current liabilities stood at $16.78M at the end of Q1 FY2026, up 18.6% from a year earlier and up 8.7% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Total current liabilities amounted to 12.4% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +18.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15.44M USD
- Year-over-year change
- -3.4%
- 4-year CAGR
- -8.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.44M | -3.4% |
| FY2024 | 2024-12-31 | 15.98M | -29.7% |
| FY2023 | 2023-12-31 | 22.73M | -6.2% |
| FY2022 | 2022-12-31 | 24.25M | +11.4% |
| FY2021 | 2021-12-31 | 21.77M | — |
Total Current Liabilities vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's Mar 2026 total current liabilities of $16.78M is the 8th highest of the 11 companies compared; the peer median is $25.36M.
- Its year-over-year change of +18.6% is the 4th highest of 11, against a peer median of +1.7%.
- Total current liabilities amounts to 12.4% of total assets for TNYA, versus a peer median of 14.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.97B | +97278.1% | +7.7% | 2.3% | |
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Mar 2026 | $46.44M | +1.1% | +17.6% | 14.8% | |
| Mar 2026 | $41.72M | +110.8% | +34.7% | 34.9% | |
| Mar 2026 | $31.05M | +72.6% | +56.1% | 15.6% | |
| Mar 2026 | $19.67M | -31.0% | -3.3% | 13.2% | |
| Mar 2026 | $17.45M | -56.6% | -28.5% | 8.0% | |
| Mar 2026 | $16.78M | +18.6% | -14.0% | 12.4% | |
| Mar 2026 | $16.53M | +14.6% | -12.6% | 25.7% | |
| Mar 2026 | $16.19M | -19.2% | -2.1% | 14.6% | |
| Mar 2026 | $8.34M | +2.3% | +5.4% | 4.7% | |
| Peer median (excluding TNYA) | $25.36M | +1.7% | +4.0% | 14.7% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38.13M | 95.27M | 45.68M | 4.32M | 100.55M |
| Short-term Investments | 213.17M | 91.26M | 58.96M | 57.12M | 0 |
| Net Receivables | 0 | 2.25M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.06M | 938K | 1.16M | 842K | 1.03M |
| Total Current Assets | 255.36M | 193.75M | 111.58M | 67.38M | 105.59M |
| Property, Plant & Equipment (Net) | 54.71M | 62.7M | 53.26M | 47.75M | 37.09M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 547K | 17.7M | 0 | 0 | 419K |
| Tax Assets | 2.46M | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.58M | 4.79M | 5.68M | 4.82M | 3.83M |
| Total Non-current Assets | 61.29M | 85.19M | 58.93M | 52.57M | 41.34M |
| Total Assets | 316.65M | 278.95M | 170.52M | 119.94M | 146.92M |
| Account Payables | 10.72M | 9.58M | 5.63M | 5.16M | 3.58M |
| Short-term Debt | 1.99M | 0 | 0 | 2.78M | 0 |
| Tax Payables | 0 | 0 | 0 | 348K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.39M | 6.97M | 9.27M | 5.81M | 6.19M |
| Total Current Liabilities | 21.77M | 24.25M | 22.73M | 15.98M | 15.44M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.81M |
| Deferred Tax Liabilities | 2.46M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 182K | 228K | 253K | 281K | 410K |
| Total Non-current Liabilities | 16.35M | 11.32M | 8.36M | 11.11M | 8.22M |
| Total Liabilities | 38.12M | 35.57M | 31.09M | 27.09M | 23.66M |
| Common Stock | 4K | 7K | 7K | 8K | 21K |
| Retained Earnings | (155.53M) | (279.2M) | (403.28M) | (514.41M) | (605.01M) |
| Accumulated OCI | (141K) | (378K) | (106K) | 28K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 278.53M | 243.38M | 139.42M | 92.85M | 123.27M |
| Total Debt | 15.7M | 15.1M | 12.42M | 13.61M | 10.83M |
| Net Debt | (22.43M) | (80.17M) | (33.26M) | 9.29M | (89.72M) |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.